PURPOSE In this study, we investigated overactive bladder (OAB) functions in male patients who used antidepressant drugs (ADs) that were previously examined in female patients, based on conflicting data in literature regarding the effects of AD on OAB and the differences between male and female urinary system physiologies (anatomical and hormonal). METHODS The study included 202 male patients...

The case report of Marti et al. highlights the interest of behavioral and cognitive therapy (BCT) in the treatment of urinary disorders, specially in overactive bladder (OAB). Despite BCT efficacy, and other similar techniques [1], this therapeutic option is not often used probably for 3 reasons: poor patient acceptance for a such treatment, cost of the BCT, and finally, lack of knowledge of th...

T first international conference on New Perspectives on the Overactive Bladder, cochaired by David R. Staskin, MD, and Alan J. Wein, MD, was held in Cambridge, Massachusetts, March 8 to 9, 2002. Conference participants were selected based on their contributions to the basic or clinical understanding of overactive bladder (OAB) and included internationally recognized specialists in urology, urol...

CONTEXT Debate exists on overactive bladder (OAB) treatment-response assessment in clinical trials and the nature and shortcomings of the different endpoints used in OAB clinical research. OBJECTIVE To evaluate current evidence and tools that measure OAB treatment response in clinical trials and to inform the development of a new multidimensional patient-reported outcome (PRO) that could be u...

To examine whether urinary tract nerve growth factor (uNGF) could be a biomarker for overactive bladder (OAB) symptom, we conducted a comprehensive meta-analysis of 8 case-control studies. In all the studies considered, patients with OAB symptom had a higher uNGF level compared to healthy people. In addition, patients had a significantly lower uNGF level after successful treatment. In the subgr...

To examine whether urinary tract nerve growth factor (uNGF) could be a biomarker for overactive bladder (OAB) symptom, we conducted a comprehensive meta-analysis of 8 case-control studies. In all the studies considered, patients with OAB symptom had a higher uNGF level compared to healthy people. In addition, patients had a significantly lower uNGF level after successful treatment. In the subgr...

Context: Within pelvic floor disorders, urinary incontinence (UI) and overactive bladder (OAB) are relevant health problems confronting the rapidly aging of modern society; this holds true also from an economic perspective. Objective: Systematise all the international available evidence on the burden of disease because of UI and OAB on

To examine whether urinary tract nerve growth factor (uNGF) could be a biomarker for overactive bladder (OAB) symptom, we conducted a comprehensive meta-analysis of 8 case-control studies. In all the studies considered, patients with OAB symptom had a higher uNGF level compared to healthy people. In addition, patients had a significantly lower uNGF level after successful treatment. In the subgr...

BACKGROUND Patients with overactive bladder (OAB) are under-diagnosed in the primary care setting. Primary care physicians (PCP) approach to the patient and appropriate patient disclosure may contribute to under-diagnosis. METHODS An outpatient primary care setting was used to determine the prevalence and characteristics of OAB. Patients who visited the family medicine outpatient clinic were ...

Overactive bladder syndrome (OAB) refers to individuals with the following symptoms: urinary urgency, increased urinary frequency, and urge incontinence. These symptoms are not life threatening but can cause embarrassment and significantly impact quality of life. There are numerous treatment options for OAB, including behavioral therapy, traditional pharmacological therapy or a combination of t...